trial · primary record
Pembrolizumab
Pancreatic Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2027-07-30 |
| Primary endpoint | Objective Response Rate (ORR) |
| Registry ID | NCT05093231 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:39.379Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05093231
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound